Aravive, Inc. (ARAV) 10-K Annual Report Thu Mar 31 2022

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2021	Mar. 25, 2022	Jun. 30, 2021
Document Information [Line Items]
Entity Central Index Key	0001513818
Entity Registrant Name	Aravive, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-36361
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-4106690
Entity Address, Address Line One	3730 Kirby Drive, Suite 1200
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77098
City Area Code	936
Local Phone Number	355-1910
Title of 12(b) Security	Common stock, par value $0.0001 per share
Trading Symbol	ARAV
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 89,127,600
Entity Common Stock, Shares Outstanding		21,094,357
Auditor Name	BDO USA, LLP
Auditor Location	Raleigh, NC
Auditor Firm ID	243

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1513818/000143774922007827/arav20211231_10k.htm

View differences made from one year to another to evaluate Aravive, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Aravive, Inc..

Continue

Assess how Aravive, Inc.'s management team is paid from their Annual Proxy

Aravive, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter by Sentiment:

All

Positive

Negative

Filter by Category:

All

Financial

Revenue

Other

Filter by Subcategory:

All

Expense

Geography

Product

Income

Other

Inside Aravive, Inc.'s 10-K Annual Report:

Financial - Expense Highlight
If the COVID-19 pandemic continues and persists for an extended period of time or increases in severity, we could experience significant disruptions to our clinical development timelines and, if we experience delays in patient enrollment and deems it necessary or advisable to improve patient recruitment by, among other things, opening additional clinical sites, we could incur increased clinical program expenses.

Financial - Expense Highlight
Our external research and development expenses consist primarily of: the cost of acquiring and manufacturing clinical trial and other materials, including expenses incurred under agreements with contract manufacturing organizations; expenses incurred under agreements with contract research organizations, investigative sites, and consultants that conduct our clinical trials; other costs associated with development activities, including additional studies; and Internal research and development costs consist primarily of salaries and related fringe benefit costs for our employees (such as workers compensation and health insurance premiums), stock-based compensation charges and travel costs.
Financial - Shares Highlight
In March 2022, we received approximately $9.3 million in net proceeds, in the aggregate, from the purchase by Eshelman Ventures, LLC and a single healthcare-focused institutional investor of 3,185,216 shares of our common stock, 1,665,025 pre-funded warrants and warrants to purchase up to 4,850,241 shares of our common stock in a registered direct offering.
Other - Other Highlight
A deliverable represents a separate performance obligation if both of the following criteria are met: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer, and (ii) the entitys promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.
Financial - Shares Highlight
On January 5, 2022, we received approximately $10.0 million from the purchase by Eshelman Ventures, LLC of pre-funded warrants to purchase up to 4,545,455 shares of our common stock.
Other - Other
At contract inception, once the...Read more
Financial - Expense
Nonrefundable advance payments for goods...Read more
Financial - Expense
Any such disruptions or delays...Read more
Financial - Expense
General and administrative expense decreased...Read more
Financial - Expense
If we had made different...Read more
Revenue - Geography
Eshelman relating to the issuance...Read more
Financial - Shares
On March 31, 2022, we...Read more
Financial - Expense
The financial terms of these...Read more
Revenue - Product
To determine revenue recognition for...Read more
Financial - Expense
The decrease was primarily driven...Read more
Other - Other
At December 31, 2021, we...Read more
Other - Other
? Incremental borrowing rate -...Read more
Other - Other
The registration statement was filed...Read more
Other - Other
In September 2020, we filed...Read more
Other - Other
Importantly, batiraxcept had a favorable...Read more
Financial - Income
The increase relates our sublease...Read more
Other - Other
The increase was primarily due...Read more
Financial - Shares
Since our inception and through...Read more
Other - Other
The intrinsic value of all...Read more
Other - Other
Our understanding of the status...Read more
Revenue - Product
Under ASC 606, we recognize...Read more
Other - Other
Our current development program benefits...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Aravive, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 21.1: Subsidaries Of The Registrant

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: ARAV
CIK: 1513818
Form Type: 10-K Annual Report
Accession Number: 0001437749-22-007827
Submitted to the SEC: Thu Mar 31 2022 3:00:48 PM EST
Accepted by the SEC: Thu Mar 31 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations